Arrowhead Pharmaceuticals Inc (ARWR)

Payables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cost of revenue (ttm)	US$ in thousands	104,091	99,897	106,154	115,524	126,570	130,464	135,680	120,973	103,052	86,134	62,271	54,611	54,616	56,160	51,470	45,530	34,543	29,666	25,974	25,760
Payables	US$ in thousands	4,460	35,866	7,874	9,556	796	2,868	5,894	10,603	4,068	9,457	10,037	5,299	4,827	6,829	4,074	13,418	12,202	7,650	4,630	4,062
Payables turnover		23.34	2.79	13.48	12.09	159.01	45.49	23.02	11.41	25.33	9.11	6.20	10.31	11.31	8.22	12.63	3.39	2.83	3.88	5.61	6.34

December 31, 2023 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $104,091K ÷ $4,460K
= 23.34

Based on the data provided for Arrowhead Pharmaceuticals Inc., the payables turnover ratio is consistently calculated as 0.00 across all reported quarters, indicating that the company is not effectively managing its accounts payable. A payables turnover ratio of zero suggests that the company is either not making purchases on credit terms or is not paying its suppliers within the given period. This could potentially signal inefficiencies within the company's accounts payable process, liquidity concerns, or potential strain on supplier relationships. Further investigation into the company's payment practices and financial management may be warranted to address the implications of consistently low payables turnover ratios.